Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-1.51 Insider Own0.10% Shs Outstand195.12M Perf Week-3.07%
Market Cap801.94M Forward P/E- EPS next Y-1.34 Insider Trans0.23% Shs Float191.59M Perf Month14.48%
Income-285.90M PEG- EPS next Q-0.39 Inst Own76.80% Short Float26.38% Perf Quarter25.69%
Sales21.30M P/S37.65 EPS this Y-44.60% Inst Trans-5.19% Short Ratio13.07 Perf Half Y-42.60%
Book/sh0.02 P/B205.50 EPS next Y13.00% ROA-57.20% Target Price5.93 Perf Year-19.09%
Cash/sh1.26 P/C3.26 EPS next 5Y- ROE-417.70% 52W Range3.02 - 8.41 Perf YTD-32.95%
Dividend- P/FCF- EPS past 5Y2.90% ROI-48.50% 52W High-51.13% Beta2.32
Dividend %- Quick Ratio1.50 Sales past 5Y-23.30% Gross Margin93.90% 52W Low36.09% ATR0.21
Employees227 Current Ratio1.50 Sales Q/Q-44.50% Oper. Margin- RSI (14)51.94 Volatility3.69% 5.04%
OptionableYes Debt/Eq109.06 EPS Q/Q-11.80% Profit Margin- Rel Volume0.32 Prev Close4.13
ShortableYes LT Debt/Eq79.28 EarningsJul 31 AMC Payout- Avg Volume3.87M Price4.11
Recom2.30 SMA20-1.53% SMA508.32% SMA200-17.57% Volume1,221,484 Change-0.48%
07-Feb-14Reiterated Stifel Buy $9 → $11
21-Jan-14Reiterated Maxim Group Buy $7.50 → $11
12-Nov-13Upgrade Maxim Group Hold → Buy $7.50
28-May-13Downgrade Maxim Group Buy → Hold $35 → $35
30-Nov-12Reiterated Stifel Nicolaus Buy $8 → $9
20-Apr-12Initiated Maxim Group Buy $9
15-Mar-12Resumed Stifel Nicolaus Buy $8
17-Aug-11Initiated Stifel Nicolaus Hold $8
18-Nov-09Downgrade Merriman Buy → Neutral
17-Jun-09Initiated Boenning & Scattergood Neutral
15-Dec-08Reiterated Lazard Capital Buy $7 → $8
24-Nov-08Reiterated Lazard Capital Buy $7
16-Oct-08Initiated Merriman Curhan Ford Buy
14-Aug-08Initiated Banc of America Sec Neutral $7
06-Aug-08Reiterated Lazard Capital Buy $12 → $10
06-Aug-08Downgrade Canaccord Adams Buy → Hold
08-Jul-08Initiated Canaccord Adams Buy $7.30
07-Dec-07Reiterated Fortis Bank Hold $10 → $9
14-Sep-07Initiated Lazard Capital Buy $14
04-Sep-07Downgrade Wachovia Outperform → Mkt Perform
08-Aug-14 01:04PM  EXELIXIS, INC. Financials EDGAR Online Financials
06-Aug-14 06:00AM  The R&D elite: America's most innovative companies at CNBC
06:00AM  The R&D elite of the market: The CNBC RQ 50 at CNBC
01-Aug-14 09:45AM  Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today at TheStreet
09:11AM  The R&D elite of the market: The CNBC RQ 50 at CNBC
31-Jul-14 05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN -5.62%
04:17PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:13PM  Exelixis Announces Second Quarter 2014 Financial Results Business Wire
04:03PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:35AM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN
07:07AM  Q2 2014 Exelixis, Inc. Earnings Release - After Market Close CCBN
25-Jul-14 09:50AM  Exelixis (EXEL) In A Perilous Reversal at TheStreet
06:34AM  Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session Zacks
22-Jul-14 05:02PM  Is this Exelixis Stock's Worst Nightmare? at Motley Fool
17-Jul-14 04:36PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online -6.03%
01:08AM  Should Roche Buy Exelixis? at Motley Fool
16-Jul-14 04:05PM  Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 Business Wire
10:04AM  Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today at TheStreet
15-Jul-14 05:36PM  Time to Fall Back in Love With Exelixis Inc.? at Motley Fool -10.51%
05:18PM  Stocks finish mixed; Yellen's comments hurt biotech and social media shares Hot Stock Minute
01:20PM  Most active Nasdaq-traded stocks AP
10:33AM  Biotechs, social stocks weak after Yellen warning at CNBC
09:52AM  Exelixis (EXEL) Is Today's Perilous Reversal Stock at TheStreet
06:38AM  Exelixis (EXEL) Soars: Stock Adds 23% in Session Zacks
14-Jul-14 05:36PM  Up 23%: Time to Buy Exelixis? at Motley Fool +22.82%
04:40PM  Roche Presents Encouraging Data on Cobimetinib Zacks
04:24PM  Why the Exelixis Cancer Trial News Matters This Time 24/7 Wall St.
03:12PM  Why Exelixis (EXEL) Stock Is SpikingToday at TheStreet
02:18PM  Why Exelixis Inc. Stock Soared at Motley Fool
01:30PM  Most active Nasdaq-traded stocks AP
12:25PM  Exelixis Sees Success in Melanoma Treatment With Drug Combination at Minyanville
11:20AM  Exelixis seen as potential target for Roche, TheStreet says at theflyonthewall.com
11:14AM  Investor Believes Roche Buys Exelixis for Skin-Cancer Drug at TheStreet
07:46AM  Roche, Exelixis Skin Cancer Drug Delays Tumor Progression at TheStreet
02:47AM  Roche skin cancer drug meets main goal in combination study Reuters
01:00AM  Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
03-Jun-14 04:15PM  Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 Business Wire
04:15PM  Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10
30-May-14 10:20AM  Why Wall Street Hates Exelixis Inc. at Motley Fool
10:20AM  Why Wall Street Hates Exelixis Inc.
29-May-14 05:06PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu EDGAR Online
05:06PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu
23-May-14 06:32PM  Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis at Motley Fool
06:32PM  Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis
20-May-14 02:44PM  Exelixis' (EXEL) Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha
02:44PM  Exelixis' (EXEL) Presents at UBS Global Healthcare Conference (Transcript)
16-May-14 06:48PM  Lightning Round: Wendy's, Hewlett-Packard, & More at CNBC
14-May-14 05:33PM  Cabozantinib and Cobimetinib to Be Featured in Ten Presentations at 2014 ASCO Annual Meeting Business Wire
05:33PM  Cabozantinib and Cobimetinib to Be Featured in Ten Presentations at 2014 ASCO Annual Meeting
13-May-14 06:34PM  Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
06:34PM  Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
09-May-14 01:04PM  EXELIXIS, INC. Financials EDGAR Online Financials
01:04PM  EXELIXIS, INC. Financials
08-May-14 04:16PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:16PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
07-May-14 01:00AM  Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib at EADO Congress 2014 Business Wire
01:00AM  Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib at EADO Congress 2014
06-May-14 04:19PM  Exelixis to Present at Two Investor Conferences in May Business Wire
01-May-14 10:57PM  Exelixis' CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
07:28PM  Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs at Motley Fool
05:00PM  Financial Results and Business Update Call scheduled for 5:00 pm ET today CCBN
04:55PM  Exelixis, Inc. Discusses Q1 2014 Results (Webcast) at Seeking Alpha
04:16PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:13PM  Exelixis Announces First Quarter 2014 Financial Results Business Wire
04:04PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
09:02AM  Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today at Motley Fool
07:34AM  Financial Results and Business Update Call scheduled for 5:00 pm ET today CCBN
07:07AM  Q1 2014 Exelixis, Inc. Earnings Release - After Market Close CCBN
28-Apr-14 01:11PM  Novel Biotech Treatments Retain Pricing Power: A Wall Street Transcript Interview with Boris Peaker, Ph.D., Executive Director and Senior Analyst with Oppenheimer & Co. Covering the Biotechnology Sector Wall Street Transcript
21-Apr-14 04:05PM  Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014 Business Wire
19-Apr-14 06:31PM  1 of These 3 Cratering Biotechs is a Buy at Motley Fool
09-Apr-14 06:00AM  3 Stocks Under $10 to Trade for Breakouts at TheStreet
04-Apr-14 12:05PM  Why I Bought Exelixis at Motley Fool
09:02AM  Morning Movers in Biotech: Celgene Corporation, Mylan, Inc. and Exelixis, Inc. at Motley Fool
06:18AM  Piper says time to buy shares of Exelixis theflyonthewall.com
03-Apr-14 09:31AM  Are These 3 Biotechs Bad News Buys? at Motley Fool
31-Mar-14 07:43PM  Exelixis Continues On at Motley Fool
03:21PM  Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today at Motley Fool
03:20PM  Which Biotech Blow-Up Is a Bad-News Buy? at Motley Fool
29-Mar-14 08:01AM  3 Horrendous Health-Care Stocks This Week at Motley Fool
28-Mar-14 09:31AM  Exelixis Inc's Comet Fails To Dazzle at Motley Fool -12.44%
07:00AM  Is This the Year Exelixis Excels? Morningstar
27-Mar-14 06:04PM  Nasdaq stocks posting largest volume increases AP
06:03PM  Most active Nasdaq-traded stocks AP
01:44PM  Most active Nasdaq-traded stocks AP
09:45AM  Trade-Ideas: Exelixis (EXEL) Is Today's "Dead Cat Bounce" Stock at TheStreet
26-Mar-14 07:33PM  Talk About High Clinical Trial Expectations at Motley Fool -39.29%
07:01PM  Why Exelixis, Inc., Plug Power Inc., and King Digital Entertainment PLC Are Today's 3 Worst Stocks at Motley Fool
06:04PM  Nasdaq stocks posting largest volume increases AP
06:04PM  Most active Nasdaq-traded stocks AP
04:48PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
03:18PM  Exelixis Plunges Most Since 2011 as Drug Trial Continues at Bloomberg
02:43PM  Biotechs still sliding, but Wall Street says don't hit panic button just yet at MarketWatch
01:16PM  Most active Nasdaq-traded stocks AP
12:19PM  On The Fly: Midday Wrap at theflyonthewall.com
12:05PM  Exelixis Enters the Danger Zone at 24/7 Wall St.
11:42AM  Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis at TheStreet
09:13AM  Todays Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam at Motley Fool
25-Mar-14 07:17PM  Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer Business Wire
04:31PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaEVP and Chief Medical OfficerFeb 15Option Exercise0.002,188071,494Feb 18 09:30 PM
KARBE FRANKEVP and CFOFeb 15Option Exercise0.001,954094,847Feb 18 09:31 PM
Lamb PeterEVP, Discovery Research & CSOFeb 15Option Exercise0.003,126035,743Feb 18 09:27 PM
SIMONTON PAMELA AEVP, ExelixisFeb 15Option Exercise0.001,875019,014Feb 18 09:28 PM
MORRISSEY MICHAELPresident and CEOFeb 15Option Exercise0.003,12503,125Feb 18 09:28 PM
SIMONTON PAMELA AEVP and General CounselNov 15Option Exercise0.001,875017,843Nov 15 09:22 PM
KARBE FRANKEVP and CFONov 15Option Exercise0.001,953093,626Nov 15 09:20 PM
Lamb PeterEVP, Discovery Research & CSONov 15Option Exercise0.005,208034,181Nov 15 09:21 PM
MORRISSEY MICHAELPresident and CEONov 15Option Exercise0.003,12503,125Nov 15 09:21 PM
Schwab GiselaEVP and Chief Medical OfficerNov 15Option Exercise0.005,312070,480Nov 15 09:21 PM
WILLSEY LANCEDirectorAug 29Buy5.1510,00051,454333,700Aug 30 06:44 PM